Menu
Amberstone Biosciences’ transformative immunotherapeutics eliminate the issues of dose toxicity interfering with drug efficacy by introducing a safer class of therapeutic agents. Traditional therapies can be extremely effective at destroying tumors. However, the high dosage required for efficacy often has devastating effects. Our technology (T-MATE™) allows us to target only the tumor without damaging healthy tissues.
Our transformative therapeutic strategy allows for revisiting targets previously deemed impossible due to high toxicity.
Our pipeline strategy is adaptable to various tumor types or auto-immune diseases.
Our therapeutics only activate under specified conditions and deactivate when conditions are no longer desirable.
Our unique combinations of engagers and agonists create an expandable portfolio of therapeutic targets.
Pipeline therapeutic discoveries start with our AmberFlow™ platform technology. Driven by proprietary single-cell microfluidics, AmberFlow™ adds the element of a directly assayable and tunable microenvironment so valuable qualitative data can be obtained much further upstream in the discovery process.
